Active substance
Acarbose
- SFDA 5
- US FDA 9
- Health Canada 2
- US price lines 3
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GLUCOBAY 100MG TAB | 100 mg | Tablet · Oral use | 30 Blister | SAR 19.75 | NCE · Prescription | BAYER PHARMA AG | Valid |
| GLUCOBAY 50MG TAB | 50 mg | Tablet · Oral use | 30 Blister | SAR 15.15 | NCE · Prescription | BAYER PHARMA AG | Valid |
| ACAROSE 100MG TABLETS | 100 mg | Tablet · Oral use | 30 Blister | SAR 19.05 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| ACAROSE 25MG TABLETS | 25 mg | Tablet · Oral use | 30 Blister | SAR 8.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| ACAROSE 50MG TABLETS | 50 mg | Tablet · Oral use | 30 Blister | SAR 15.00 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2; HYPOGLYCEMIA - POSTPRANDIAL HYPERINSULINEMIC HYPOGLYCEMIA AFTER GASTRIC BYPASS SURGERY
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | WATSON LABS | Prescription | 7 May 2008 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | HIKMA PHARMS | Prescription | 7 May 2008 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | IMPAX LABS | Prescription | 14 May 2009 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | STRIDES PHARMA | Prescription | 27 Jul 2011 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | SOMERSET THERAPS LLC | Prescription | 17 Oct 2013 |
| PRECOSE | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | BAYER HLTHCARE | Discontinued | 6 Sep 1995 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | NATCO PHARMA USA | Discontinued | 6 Jan 2011 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | AVET LIFESCIENCES | Discontinued | 7 Feb 2012 |
| ACARBOSE | 25MG; 50MG; 100MG | tablet · oral | HANGZHOU ZHONGMEI | Discontinued | 18 Aug 2020 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MAR-ACARBOSE | 02494078 | 50 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ACARBOSE | 02494086 | 100 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ACARBOSE 100 MG TABLET | $0.27398 | per EA | 23 Sep 2026 |
| US NADAC | ACARBOSE 25 MG TABLET | $0.17982 | per EA | 23 Sep 2026 |
| US NADAC | ACARBOSE 50 MG TABLET | $0.16905 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Acarbose 100mg tablets | £35.32 | 90 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Acarbose 50mg tablets | £34.54 | 90 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.